PAVmed (NASDAQ: PAVM) is one of 113 public companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare PAVmed to similar companies based on the strength of its earnings, profitability, risk, institutional ownership, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a breakdown of recent recommendations for PAVmed and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PAVmed 0 0 1 0 3.00
PAVmed Competitors 640 2352 4473 211 2.55

PAVmed currently has a consensus price target of $5.00, indicating a potential upside of 354.55%. As a group, “Surgical & medical instruments” companies have a potential upside of 379.37%. Given PAVmed’s competitors higher possible upside, analysts clearly believe PAVmed has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares PAVmed and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
PAVmed N/A -$9.51 million -2.12
PAVmed Competitors $1.44 billion $104.34 million -168.89

PAVmed’s competitors have higher revenue and earnings than PAVmed. PAVmed is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares PAVmed and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PAVmed N/A N/A -171.55%
PAVmed Competitors -38.83% -90.96% -18.39%

Volatility and Risk

PAVmed has a beta of -0.67, suggesting that its share price is 167% less volatile than the S&P 500. Comparatively, PAVmed’s competitors have a beta of 0.81, suggesting that their average share price is 19% less volatile than the S&P 500.

Insider & Institutional Ownership

6.7% of PAVmed shares are owned by institutional investors. Comparatively, 49.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 29.2% of PAVmed shares are owned by company insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


PAVmed competitors beat PAVmed on 7 of the 13 factors compared.

PAVmed Company Profile

PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with's FREE daily email newsletter.